# A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

> **NCT00234520** · — · COMPLETED · sponsor: **Ipsen** · enrollment: 225 (actual)

## Conditions studied

- Acromegaly

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00234520
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2005-02-18
- **Final completion:** 2005-02-18
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234520, "A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00234520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*